Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 5156

Next Previous
X
Search
Drug Profile

AZD 5156

Alternative Names: AZD-5156; Cilgavimab/AZD 3152

Latest Information Update: 13 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III COVID 2019 infections

Most Recent Events

  • 06 Feb 2023 Phase-III clinical trials in COVID-2019 infections (In adolescents, In children, In adults, In the elderly, Prevention) in Turkey, Taiwan, Spain, South Africa, Poland, South Korea, France, Argentina, Argentina, USA (IM) (NCT05648110)
  • 12 Jan 2023 Phase-III clinical trials in COVID-2019 infections (In adolescents, In children, In the elderly, Prevention, In adults) in United Kingdom (IM) (NCT05648110)
  • 21 Dec 2022 AstraZeneca plans a phase-III (SUPERNOVA) trial for COVID-2019 infections (Prevention, In adolescents, In adults, In children, In the elderly) in Argentina, Denmark, France, South Africa, Taiwan, Turkey and United Kingdom by end of December 2022 (IM) (NCT05648110)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top